Is the Palvella Therapeutics (PVLA) investment thesis intact?

Yes. Readouts currently rates the Palvella Therapeutics Thesis Intact. FDA accepts Palvella's lead NDA; February 28, 2027 decision target set.

What is the next catalyst for Palvella Therapeutics (PVLA)?

The next dated event is Phase 2 start for QTORIN pitavastatin, expected Q4 2026, as stated by the company. Also ahead: Phase 3 start for QTORIN rapamycin, expected Q4 2026.

PVLAPalvella Therapeutics, Inc.

⚡

Palvella Therapeutics Inc (PVLA) (Q3 2026) Earnings Call Highlights: FDA Priority Review, $236. ... - Yahoo Finance

Yahoo Finance · Nov 5, 11:16 PM

⚡

Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance

Yahoo Finance · Nov 5, 12:30 PM

Market reactionShares rose 12% on Nov 6.

IntactLast material event Oct 12, 2026 · Updated Oct 28, 2026

FDA accepts Palvella's lead NDA; February 28, 2027 decision target set

Palvella develops topical gels for rare skin and vascular diseases; its lead, QTORIN rapamycin, is under FDA review for microcystic lymphatic malformations and is not approved anywhere.

Palvella's investment case centers on topical QTORIN rapamycin becoming the first approved treatment for microcystic lymphatic malformations. Single-arm Phase 3 SELVA met its endpoints; FDA has accepted the NDA with Priority Review and a February 28, 2027 action target. A U.S. launch is planned in the first half of 2027, subject to approval. Cash and investments of $250.6 million at June 30, 2026 support development, including planned venous malformation and DSAP trials, while angiokeratoma results offer further expansion potential.

Thesis checklist

0 risks need attention

Select a row for evidence

What must be trueStateNext proof

FDA approves QTORIN rapamycinAwaiting evidenceFDA's action on the NDA and, if approved, the permitted patient population and prescribing requirements.Next: FDA's action on the NDA and, if approved, the permitted patient population and prescribing requirements.

Why it is in this state

The evidence, what would weaken it and the source filing

SELVA results hold up in reviewSupportedFDA's assessment of SELVA's efficacy and safety package during NDA review.Next: FDA's assessment of SELVA's efficacy and safety package during NDA review.

Why it is in this state

The evidence, what would weaken it and the source filing

Venous malformation Phase 3 startsAwaiting evidenceCompletion of the End-of-Phase 2 meeting and announcement of the Phase 3 start.Next: Completion of the End-of-Phase 2 meeting and announcement of the Phase 3 start.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash funds launch and Phase 3SupportedUpdated cash balances and spending as launch preparations and clinical programs advance.Next: Updated cash balances and spending as launch preparations and clinical programs advance.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

FDA decision on QTORIN rapamycin

Tests: FDA approves QTORIN rapamycin

February 28, 2027 PDUFA target action date

Does FDA approve QTORIN rapamycin for microcystic lymphatic malformations on terms that support the planned launch?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentClinical

-4.4%Oct 12, 2026

FDA accepts Palvella's lead NDA; February 28, 2027 decision target set

IntactClinical

-7.0%Jul 14, 2026

Phase 3 win and rolling NDA filed for a topical rapamycin with no approved rival; approval in H1 2027 is the single gate

IntactClinical

+5.8%May 20, 2026

QTORIN rapamycin bets on NDA approval for microcystic LMs, with FDA's regulatory decision as the singular inflection point

IntactClinical

+37.1%Feb 24, 2026

Phase 3 SELVA QTORIN rapamycin primary endpoint met

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Microcystic lymphatic malformations

QTORIN rapamycin · 2 upcoming · 2 completed

Regulatory Decision

February 28, 2027

Commercial Launch

H1 2027

Disseminated superficial actinic porokeratosis

QTORIN pitavastatin · 1 upcoming · 1 completed

Phase 2 Study Initiation

Q4 2026

Additional rare skin diseases

QTORIN rapamycin · 1 upcoming

Fourth indication announcement

Q4 2026

Cutaneous venous malformations

QTORIN rapamycin · 2 upcoming · 1 completed

Phase 3 Study Initiation

Q4 2026

End-of-Phase Meeting

TBD

Undisclosed rare disease

QTORIN platform (undisclosed) · 1 upcoming

Third QTORIN platform product candidate announcement (rare disease)

Q4 2026

Clinically significant angiokeratomas

QTORIN rapamycin · 1 upcoming · 2 completed

Phase 2 Data: ToplineLOTU

H2 2027

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Palvella Therapeutics (PVLA) investment thesis intact?: Yes. Readouts currently rates the Palvella Therapeutics Thesis Intact. FDA accepts Palvella's lead NDA; February 28, 2027 decision target set.
What is the next catalyst for Palvella Therapeutics (PVLA)?: The next dated event is Phase 2 start for QTORIN pitavastatin, expected Q4 2026, as stated by the company. Also ahead: Phase 3 start for QTORIN rapamycin, expected Q4 2026.

Other companies we cover in these diseases

Microcystic lymphatic malformations: Quoin Pharmaceuticals (QNRX)

Drug pages: QTORIN rapamycin
Disease areas: Skin diseases, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.